Medical Outcomes and Research in Economics Research Group, Sunnybrook Research Institute, Toronto, ON, Canada.
Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):553-67. doi: 10.1586/erp.12.45. Epub 2012 Nov 11.
Palivizumab prophylaxis has been demonstrated to reduce the number of hospitalizations attributable to respiratory syncytial virus in high-risk infants. However, as palivizumab acquisition costs are high, quantifying cost-effectiveness is important. The primary aim of this review was to examine the cost-effectiveness of palivizumab across numerous indications in high-risk infants and to report on factors that may impact outcomes. A systematic literature search was conducted to identify pharmacoeconomic analyzes of palivizumab compared to no prophylaxis for respiratory syncytial virus in infants and young children. A total of 28 articles met inclusion criteria and were subsequently assigned quality scores according to the Quality of Health Economic Studies criteria. Results varied according to perspective, input parameters, outcome measures, populations and base-case and sensitivity analyses. Overall, cost-effectiveness results were inconsistent. Some studies reported favorable outcomes, while others did not, or were inconclusive. Factors to consider in the interpretation of such economic evaluations are discussed.
帕利珠单抗预防治疗已被证实可降低高危婴儿因呼吸道合胞病毒而住院的人数。然而，由于帕利珠单抗的采购成本较高，因此量化其成本效益非常重要。本综述的主要目的是检查帕利珠单抗在高危婴儿的多种适应证中的成本效益，并报告可能影响结果的因素。系统地进行了文献检索，以确定与呼吸道合胞病毒预防治疗相比，帕利珠单抗在婴儿和幼儿中的药物经济学分析。共有 28 篇文章符合纳入标准，并根据健康经济研究标准的质量标准对其进行了质量评分。结果因观点、输入参数、结果衡量标准、人群以及基础案例和敏感性分析而异。总体而言，成本效益结果不一致。一些研究报告了有利的结果，而其他研究则没有，或者没有定论。讨论了在解释这些经济评估时需要考虑的因素。
